Dimitrios Tsiachris | Medicine | Best Researcher Award

Assist. Prof. Dr. Dimitrios Tsiachris | Medicine | Best Researcher Award

EP and Pacing Lab Director | National and Kapodestrian University of Athens | Greece

Dr. D. L. Tsiachris is a highly accomplished cardiovascular researcher and clinician whose work has profoundly influenced the fields of cardiac electrophysiology and interventional cardiology. With an extensive research portfolio encompassing 224 scientific publications, 4,004 citations, and a Scopus h-index of 34, his contributions have advanced the understanding and management of complex cardiac rhythm disorders. His primary research interests lie in atrial fibrillation, ventricular arrhythmias, catheter ablation, and cardiac resynchronization therapy, with particular emphasis on novel energy-based interventions such as pulsed field ablation, cryoballoon technology, and radiofrequency systems. Dr. Tsiachris possesses exceptional research skills in clinical trial design, data synthesis, systematic reviews, and meta-analysis, enabling him to provide robust evidence supporting safer and more effective therapeutic strategies for patients with structural and electrical heart diseases. His investigations into leadless pacing systems, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, and the optimization of device-based therapies have contributed to personalized and precision-based cardiology. In addition, his studies on patient-reported outcomes and long-term ablation success rates bridge the gap between procedural innovation and patient-centered care. Recognized for his scientific leadership and collaborative excellence, Dr. Tsiachris has co-authored with more than 700 international researchers and continues to influence clinical practice guidelines through his impactful findings. Though his work is primarily published in high-impact journals such as Heart Rhythm, Europace, and Journal of Clinical Medicine, his commitment to advancing cardiovascular science stands as his greatest distinction. Honored for his research excellence and global contributions to electrophysiology, Dr. D. L. Tsiachris remains a driving force in redefining the standards of modern cardiac care through innovation, precision, and evidence-based practice.

Profiles: Scopus | ORCID | Google Scholar

Featured Publications

Gatzoulis, K. A., Tsiachris, D., Arsenos, P., et al. (2019). Arrhythmic risk stratification in post-myocardial infarction patients with preserved ejection fraction: The PRESERVE EF study. European Heart Journal, 40(35), 2940–2949.

Gatzoulis, K. A., Vouliotis, A. I., Tsiachris, D., et al. (2013). Primary prevention of sudden cardiac death in a nonischemic dilated cardiomyopathy population: Reappraisal of the role of programmed ventricular stimulation. Circulation: Arrhythmia and Electrophysiology, 6(3), 504–512.

Gatzoulis, K. A., Tsiachris, D., et al. (2018). Programmed ventricular stimulation predicts arrhythmic events and survival in hypertrophic cardiomyopathy. International Journal of Cardiology, 254, 175–181.

Silberbauer, J., Tsiachris, D., et al. (2014). Noninducibility and late potential abolition: A novel combined prognostic procedural end point for catheter ablation of postinfarction ventricular tachycardia. Circulation: Arrhythmia and Electrophysiology, 7(3), 424–435.

Della Bella, P., Tsiachris, D., et al. (2013). Management of ventricular tachycardia in the setting of a dedicated unit for the treatment of complex ventricular arrhythmias: Long-term outcome after ablation. Circulation, 127(13), 1359–1368.

Dr. Mokgata A. Matjie’s research advances human resource and organizational management by promoting fairness, emotional intelligence, and performance excellence. His work strengthens institutional effectiveness, employee well-being, and leadership accountability—driving innovation in workplace culture and public sector transformation globally.

Hengrui Liu | Medicine | Best Researcher Award

Prof. Dr. Hengrui Liu | Medicine | Best Researcher Award

Researcher | University of Cambridge | United Kingdom

Dr. Hengrui Liu is a distinguished researcher at the University of Cambridge, United Kingdom, whose interdisciplinary work spans molecular biology, oncology, pharmacogenomics, and bioinformatics. With a remarkable Scopus h-index of 31, over 2,300 citations, and 55 publications, Dr. Liu has made substantial contributions to understanding cancer biology and translational medicine. His research integrates computational modeling, systems biology, and experimental oncology, focusing on identifying molecular mechanisms underlying drug resistance, tumor progression, and therapeutic targeting.One of Dr. Liu’s notable contributions includes the use of CRISPR screening and cell line IC50 data to uncover genes responsible for trametinib resistance, highlighting potential pathways for targeted cancer therapy. He also explores the role of transcription factors in protein autoubiquitination across multiple cancer types through pan-cancer in-silico profiling, advancing precision oncology approaches. His expertise extends to traditional medicine and integrative therapies, as seen in his recent studies on the role of traditional Chinese medicine (TCM) in improving liver transplantation outcomes, bridging conventional and modern biomedical practices.Dr. Liu’s recent review on the multidimensional role of laminin γ2 (LAMC2) in cancer progression provides a comprehensive understanding of how extracellular matrix components influence tumor behavior and metastasis. His interdisciplinary research brings together molecular mechanisms, clinical relevance, and computational insight, reflecting a holistic approach to biomedical innovation. Moreover, his collaborative network of over 100 co-authors underscores his global impact and leadership in international scientific research.Through his pioneering studies, Dr. Hengrui Liu contributes to the development of novel therapeutic strategies, drug resistance biomarkers, and predictive computational frameworks that enhance the diagnosis, treatment, and prognosis of complex diseases such as cancer. His work exemplifies the synergy between data-driven research and molecular experimentation, reinforcing his reputation as a forward-thinking scientist shaping the future of personalized medicine and biomedical innovation.

Profiles: Scopus | ORCID | Google Scholar

Featured Publications

Liu, H., et al. (2025). CRISPR screening and cell line IC50 data reveal novel key genes for trametinib resistance. Open-access Letter. 26 citations.

Liu, H., et al. (2025). In vitro antibacterial activity of neochebulinic acid from aqueous extract of Terminalia chebula Retz against Helicobacter pylori. BMC Complementary Medicine and Therapies. 1 citation.

Liu, H., et al. (2025). An in-silico pan-cancer bulk and single-cell profiling of transcription factors in protein autoubiquitination. Discover Oncology. 2 citations.

Liu, H., et al. (2025). The multidimensional role of laminin γ2 (LAMC2) on cancer progression. Review Article. 0 citations.

Liu, H., et al. (2025). Role of traditional Chinese medicine in supporting liver transplantation outcomes. World Journal of Transplantation. 4 citations.